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Background: Open-label, parallel-group, international trial comparing aztreonam for inhalation solution (AZLI) and tobramycin nebulizer solution
(TNS) for cystic ﬁbrosis patients with airway Pseudomonas aeruginosa.
Methods: 273 patients (≥6 years); randomized to three 28-day courses (AZLI 75 mg [three‐times/day] or TNS 300 mg [twice/day]); 28 off-days
separated each course.
Results: 268 patients were treated (AZLI/TNS: 136/132). Mean baseline FEV1 was 52% predicted. Mean relative changes after 1 course (AZLI:
8.35%; TNS: 0.55%; pb0.001) and mean actual changes across 3 courses (AZLI: 2.05%; TNS: −0.66%; p=0.002) indicated AZLI statistical
superiority vs. TNS. AZLI-treated patients had fewer respiratory hospitalizations (p=0.044) and respiratory events requiring additional
antipseudomonal antibiotics (p=0.004); both treatments were well tolerated. 133 patients received 1 to 3 courses of AZLI treatment in the open-
label extension-period (28-day courses separated by 28 days off-treatment); lung function improvements were comparable regardless of whether
patients had received TNS or AZLI in the preceding comparative period.
Conclusions: AZLI demonstrated statistical superiority in lung function and a reduction in acute pulmonary exacerbations compared to TNS over 3
treatment courses (ClinicalTrials.gov: NCT00757237).
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Inhaled antipseudomonal antibiotics are standard of care
for cystic fibrosis (CF) patients with chronic Pseudomonas
aeruginosa (PA) airway infection [1,2]. Relatively high
delivered drug dose maximizes airway concentrations, and
low systemic absorption reduces side effects. Three inhaled
antipseudomonal antibiotics with different mechanisms of action
are available for treating CF patients: tobramycin nebulizer
solution (TNS; an aminoglycoside), colistimethate sodium
(colistin; a polymyxin; not licensed in the US), and aztreonam
for inhalation solution (AZLI; a monobactam) [3–8]. TNS has
proven efficacy for CF patients, and established the standard of
care of every other month inhaled antibiotic treatment for
suppression of chronic airway infection [9]. Since AZLI was
recently approved, it is appropriate to evaluate it against standard
of care, given the ongoing need for more effective and better
tolerated inhaled antibiotic treatments.
AZLI is a lyophilized formulation of the monobactam
antibiotic aztreonam, specifically designed for inhalation therapy
with lysine as an excipient [7,8,10]. In previous placebo-
controlled clinical trials, efficacy and safety of AZLI were
demonstrated in patients with CF and PA airway infection who
previously received TNS treatment and in patients with
relatively little previous TNS exposure. Additionally, thera-
peutic benefits observed in the placebo-controlled trials
were sustained across 18 months of open-label treatment
[11–13].
The trial described herein compared the efficacy and safety of
AZLI to TNS, across three 28‐day treatment courses. An optional
open‐label extension period for eligible patients included 3
additional AZLI treatment courses.2. Methods
2.1. Study design
This open-label, randomized, parallel-group, active-
comparator study was conducted at 91 CF‐centers in Europe
and the US (August 2008–May 2010). Eligible patients were
randomized (1:1) to three 28-days on/28 days off treatment
courses of AZLI (Cayston®, Gilead Sciences Inc.) 75 mg three‐
times daily or TNS (TOBI®, Novartis Pharmaceuticals Corp.)
300 mg twice daily (Online Fig. 1) [3,4,7,8]. The 26‐week
active-comparator period was followed by an optional, 24‐week,
open‐label, single‐arm, extension period of 3 AZLI treatment-
cycles for eligible patients at European study sites (completed: Nov
2010).
The study was conducted in accordance with principles of
the Declaration of Helsinki (as amended in Edinburgh, Tokyo,
Venice, Hong Kong, and South Africa), International Confer-
ence on Harmonisation guidelines, Good Clinical Practice
principles, and laws/regulations of each study location. Institu-
tional Review Boards/Ethics Committees approved the study for
each site. Patients/parents provided written informed consent/
assent prior to undergoing study procedures.2.2. Participants
Eligible patients (≥6 years of age) had a documented
CF diagnosis, PA-positive sputum culture within the previous
3 months, and FEV1 ≤75% predicted at screening. Additional
TNS use was prohibited during the active-comparator period.
Additional antipseudomonal antibiotics could be administered
for symptoms consistent with the diagnosis of acute pulmo-
nary exacerbation: decreased exercise tolerance, increased
cough, increased sputum/chest congestion, or decreased
appetite [14]. Patients receiving additional antipseudomonal
antibiotics at any point after randomization could continue
study treatments.2.3. Study endpoints
Co-primary efficacy endpoints were designed to satisfy
registrational requirements based on European Medicines Agency
and the US Food and Drug Administration guidance: non‐
inferiority of AZLI for relative change in FEV1% predicted at
Day 28 and superiority of AZLI for actual change in FEV1%
predicted across 3 treatment cycles. Selected secondary and
tertiary endpoints were: time-to-need for IV antipseudomonal
antibiotics for respiratory events, change from baseline on
cystic fibrosis questionnaire—revised (CFQ-R) respiratory
symptoms scale (RSS), number of respiratory hospitalizations,
additional antipseudomonal antibiotic use, weight change from
baseline, change in sputum PA density (colony forming units
per gram sputum [CFU/g]), and responses to the treatment
satisfaction questionnaire for medication (TSQM) [15, 16]. An
independent, blinded data adjudication committee determined
respiratory hospitalizations and respiratory events requiring
additional antipseudomonal antibiotics.2.4. Statistical analysis
Statistical analyses were performed on the intent-to-treat
(ITT) population: randomized patients receiving ≥1 dose
of AZLI/TNS. The primary non‐inferiority endpoint was
assessed with an analysis of covariance (ANCOVA) model
with terms for treatment, baseline FEV1% predicted (contin-
uous variable), and inhaled tobramycin use in previous
year (≥84, b84 days). If the 95% confidence interval (CI;
2-sided) lower boundary for the treatment difference (AZLI–
TNS) was N−4% (pre‐specified non‐inferiority margin),
non-inferiority of AZLI to TNS was concluded. Superiority
was concluded if the lower limit of the 95% CI was above
zero (i.e., pb0.05).
The primary superiority endpoint was the average least‐
square means from Weeks 4, 12, and 20 visits, based on a
mixed-effect model repeated measures (MMRM) analysis
method outlined by Siddiqui, which included terms for treatment,
baseline FEV1% predicted (continuous variable), inhaled
tobramycin use (≥84, b84 days), visit, and treatment/visit
interaction [17].
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3.1. Disposition
Of 273 randomized patients, 268 received treatment with AZLI
(n=136) or TNS (n=132); 233 patients (85.3%) completed the
active-comparator period (Fig. 1). Mean use of distributed vials
was 94.0% (AZLI) and 94.2% (TNS). Of 169 eligible patients, 133
(78.7%) entered the open‐label extension period (AZLI: 68; TNS:
65), and 118 patients completed 3 AZLI courses (88.7%).
3.2. Patient characteristics
Patient characteristics were balanced between treatment
groups (Table 1). Mean age was 25.5 years, with 78.0% of
patients ≥18 years of age (n=209/268). FEV1 was ≤50%
predicted for 43.7% of patients (n=117). Inhaled tobramycin
use ≥84 days in the previous year (equivalent to at least three
28-day courses) was reported for 85.1% of patients (n=228).Fig. 1. Patient disposition. Efficacy and safety analyses for the active-comparator pe
randomized and treated patients (AZLI: 136; TNS: 132).The 40 patients (AZLI: 21, TNS: 19) with inhaled tobramycin
use b84 days during the previous year were a heterogeneous
group: 25 used no tobramycin in the previous year, some used
inhaled tobramycin more than 1 year prior, and many had
used inhaled colistin. The incidence of multi-drug resistant PA
for cohorts with b84 or≥84 days of inhaled tobramycin use in the
previous year was comparable (34.4% vs. 30.6%, respectively),
indicating significant prior antibiotic exposure in both groups.
Characteristics of the 133 European patients who entered the
extension period were similar to those of the overall group.3.3. Efficacy — active-comparator period
Mean relative changes from baseline FEV1% predicted at Day
28 were 8.35% (AZLI) and 0.55% (TNS; Fig. 2A). The treatment
difference (AZLI–TNS) was 7.80% (95% CI=3.86%, 11.73%;
pb0.001). The lower CI boundary was N0, indicating AZLI was
superior to TNS.riod were conducted on the intent to treat (ITT) population, which included 268
Table 1
Baseline demographic and clinical characteristics.
AZLI-treated n=136 TNS-treated n=132 Overall n=268
Region; n (%)
Europe 92 (67.6) 82 (62.1) 174 (64.9)
United States 44 (32.4) 50 (37.9) 94 (35.1)
Age, years; mean (SD) 25.8 (9.1) 25.1 (9.0) 25.5 (9.0)
Age group; n (%)
6 to 12 years 8 (5.9) 5 (3.8) 13 (4.9)
N12 to b18 years 20 (14.7) 26 (19.7) 46 (17.2)
≥18 years 108 (79.4) 101 (76.5) 209 (78.0)
Male gender; n (%) 68 (50.0) 66 (50.0) 134 (50.0)
White race; n (%) 130 (95.6) 131 (99.2) 261 (97.4)
Body mass index, kg/m2; mean (SD) 20.2 (3.0) 20.5 (2.8) 20.4 (2.9)
CFTR genotype; a n (%)
Homozygous for Δ508 64 (54.7) 60 (54.1) 124 (54.4)
Heterozygous for Δ508 36 (30.8) 30 (27.0) 66 (28.9)
Unidentified or other 17 (14.5) 21 (18.9) 38 (16.7)
FEV1% predicted at screening; n (%)
N50% to ≤75% 76 (55.9) 75 (56.8) 151 (56.3)
≤50% 60 (44.1) 57 (43.2) 117 (43.7)
b25% 6 (4.4) 6 (4.5) 12 (4.5)
Inhaled tobramycin use in previous year; b n (%)
b84 days 21 (15.4) 19 (14.4) 40 (14.9)
≥84 days 115 (84.6) 113 (85.6) 228 (85.1)
Inhaled colistin use in previous year; c n (%) 50 (36.8%) 53 (40.2%) 103 (38.4%)
Azithromycin use at baseline; n (%) 85 (62.5) 89 (67.4) 174 (64.9)
Dornase alfa use at baseline; n (%) 92 (67.6) 91 (68.9) 183 (68.3)
Hypertonic saline use at baseline; n (%) 44 (32.4) 46 (34.8) 90 (33.6)
Baseline values; mean (SD)
FEV1% predicted 52.3 (15.6) 52.2 (14.6) 52.3 (15.1)
FEV1 (L) 1.8 (0.6) 1.8 (0.6) 1.8 (0.6)
Log10 PA CFU per g sputum
d 6.4 (2.1) 5.9 (2.7) 6.2 (2.4)
CFQ-R respiratory symptoms score e 62.9 (20.4) 58.0 (20.8) 60.4 (20.7)
MIC of aztreonam for all PA isolates at baseline f
MIC50; μg/mL 2 2 2
MIC90; μg/mL 32 128 64
Minimum MIC; μg/mL ≤1 ≤1 ≤1
Maximum MIC; μg/mL N2048 2048 N2048
Isolates tested; n 208 198 406
MIC of tobramycin for all PA isolates at baseline f
MIC50; μg/mL 2 2 2
MIC90; μg/mL 64 64 64
Minimum MIC; μg/mL ≤0.12 ≤0.12 ≤0.12
Maximum MIC; μg/mL N1024 N1024 N1024
Isolates tested; n 208 198 406
Multi-drug resistant PA; f,g n (%) 35 (30.4) 35 (31.8) 70 (31.1)
a n=117, 111, 228 for 3 columns.
b Enrollment included ≤40 patients with b84 days inhaled tobramycin use in the previous year. One patient was mistakenly stratified to ≥84 days and 2 patients
were mistakenly stratified to b84 days.
c Colistin is not licensed in the US.
d n=102, 103, and 205 for 3 columns.
e n=131, 131, and 262 for 3 columns.
f n=115, 110, and 225 for 3 columns.
g Resistance assessed using CF Foundation definition: resistance to all antibiotics tested in 2 of the 3 drug classes (aminoglycosides, beta-lactams, quinolones) [18].
CFQ-R = cystic fibrosis questionnaire—revised; CFTR = cystic fibrosis transmembrane conductance regulator; CFU = colony forming units; FEV1 = forced
expiratory volume in 1 s; MIC = minimum inhibitory concentration; PA = Pseudomonas aeruginosa.
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3 treatment courses were 2.05% (AZLI) and −0.66% (TNS).
The treatment difference (AZLI–TNS) was 2.70% (p=0.002;
Fig. 2B), again demonstrating AZLI superiority over TNS.
Both mean relative change and mean actual change from
baseline FEV1% predicted were significantly larger for AZLI‐treated than for TNS‐treated patients after each on-treatment
course (Fig. 2A, B).
Across 3 treatment cycles in the active-comparator period,
mean relative changes in FEV1% predicted were 3.11% (AZLI)
and −0.29% (TNS). The treatment difference (AZLI–TNS) was
statistically significant (3.4%, p=0.02). The treatment difference
A B
C D
Fig. 2. Change in FEV1% predicted. A. Adjusted mean relative change from baseline FEV1% predicted (MMRM analysis). The difference between AZLI and TNS
after the first treatment course (Day 28) was the non‐inferiority co‐primary efficacy endpoint, shown by the arrow; results shown in the box were based on an
ANCOVA analysis, as described in the Methods section. AZLI–TNS treatment differences were 6.77 at Week 2 (pb0.001); 7.88 at Week 4 (pb0.001); 6.04 at Week
12 (p=0.007), and 5.89 at Week 20 (p=0.004). B. Adjusted mean actual change from baseline FEV1% predicted (MMRM analysis). The difference between AZLI
and TNS across 3 treatment courses was the superiority co-primary efficacy endpoint, as described in the box. AZLI–TNS treatment differences were 3.24 at Week 2
(pb0.001); 3.35 at Week 4 (pb0.001); 2.61 at Week 12 (p=0.02), and 2.15 at Week 20 (p=0.03). C. Adjusted mean relative change from baseline FEV1% predicted,
with censoring for additional antibiotic use. The MMRM analysis shown in panel A was repeated with censoring of subsequent FEV1% predicted values after a
course of IV/inhaled antipseudomonal antibiotics was prescribed for treatment of respiratory symptoms. AZLI–TNS treatment differences (trt. diff.) are shown at
Week 2 (pb0.001), Week 4 (pb0.001), Week 12 (p=0.002) and Week 20 (p=0.005). Patients censored: AZLI-treated 52, TNS-treated 76. D. Adjusted mean relative
change from baseline FEV1% predicted, for patients participating in the open-label AZLI extension period. The MMRM analysis shown in panel A was repeated for
this patient population. TNS/AZLI patients received TNS during the active-comparator period and AZLI during the open-label extension period.
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study visits favored AZLI and approached statistical significance
(AZLI: 0.85%, TNS: −0.5%; treatment difference 1.35%, p=
0.066).
AZLI–TNS differences in mean relative change from baseline
FEV1% predicted at Day 28 were statistically significant for
several subgroups (Online Fig. 2).
Average change from baseline CFQ-R RSS across 3 treatment
cycles was significantly larger for AZLI-treated than for TNS‐
treated patients (Table 2). Decreases in sputum PA density after
each course were similar for AZLI and TNS-treated patients.
AZLI-treated patients demonstrated weight gains above baseline at
each study visit, while TNS-treated patients' bodyweight remained
at or below baseline. Differences favoring AZLI were statistically
significant at Weeks 4, 12, and 16, but not at Week 24. Scores on
the TSQM effectiveness and global satisfaction scales were
significantly higher for AZLI‐treated than TNS-treated patients.Fewer AZLI‐treated patients received additional IV and/or
inhaled antipseudomonal antibiotics for respiratory events
(AZLI: 38% vs. TNS: 58%; p=0.002; Table 2). Significantly
fewer respiratory events requiring IV and/or additional inhaled
antipseudomonal antibiotics (AZLI: 84, TNS: 121; p=0.004)
and fewer respiratory hospitalizations (AZLI: 40, TNS: 58; p=
0.044) occurred in AZLI-treated patients.
Using Kaplan–Meier methods, median time-to-need for IV
antipseudomonal antibiotics for respiratory events was signifi-
cantly longer for AZLI‐treated than for TNS‐treated patients (p=
0.003; Table 2; Fig. 3).
To account for the confounding effect of additional antibiotic
use on lung function, a post-hoc MMRM analysis of relative
change from baseline FEV1% predicted was performed, censor-
ing FEV1% predicted values for individual patients subsequent to
their receiving a course of IV/inhaled antipseudomonal antibi-
otics (Fig. 2C). Compared with the primary analysis, FEV1%
Table 2
Selected secondary and tertiary efficacy endpoints.
Endpoint AZLI-treated
n=136
TNS-treated
n=132
p-Value
Time to need for IV antipseudomonal antibiotics for respiratory events a
Median number of days (95% CI) NE (177, NE) 151 (113, NE) 0.003
Event rate at Week 24 (end of active-comparator period), % 36 54
Time-to-first respiratory hospitalization a
Median number of days (95% CI) NE (NE, NE) NE (NE, NE) 0.111
Event rate at Week 24 (end of active-comparator period), % 24 31
CFQ-R respiratory symptoms scale, change from baseline score, b adjusted mean (SE)
Week 4 (after course 1; AZLI: n=131; TNS: n=131) 8.2 (1.7) 2.6 (1.7) 0.005
Average across 3 courses (Weeks 4, 12, 20; AZLI: n=131; TNS: n=131) 6.3 (1.5) 2.2 (1.5) 0.019
Number of respiratory hospitalizations c 40 58 0.044
Number of respiratory events requiring IV and/or additional inhaled antipseudomonal antibiotics c 84 121 0.004
Patients requiring IV and/or additional inhaled antipseudomonal antibiotics for respiratory events, d n (%) 52 (38.2) 76 (57.6) 0.002
Time to need for IV or additional inhaled antipseudomonal antibiotics for respiratory events a
Median number of days (95% CI) NE (177, NE) 117 (102, 169) b0.001
Event rate at Week 24 (end of active-comparator period), % 38 58
Days of oral, IV, and/or additional inhaled antipseudomonalantibiotic use, e mean (SD) 21.3 (24.8) 28.4 (31.5) 0.060
Log10 PA CFU/g sputum, change from baseline,
b adjusted mean (SE)
Week 4 (after course 1; AZLI: n=88; TNS: n=94) −0.60 (0.23) −0.34 (0.23) 0.330
Average across 3 courses (Weeks 4, 12, 20; AZLI: n=97; TNS: n=97) −0.55 (0.19) −0.32 (0.19) 0.295
Weight, relative change from baseline at Week 24 (end of active‐comparator period), b %, adjusted mean (SE) 0.58 (0.41) 0.06 (0.43) 0.289
TSQM scales, b Week 4 (after course 1), adjusted mean (SE)
Effectiveness (AZLI: n=131; TNS: n=126) 69.5 (1.9) 56.9 (2.0) b0.001
Side-effects (AZLI: n=130; TNS: n=126) 91.6 (1.6) 89.2 (1.7) 0.204
Convenience (AZLI: n=129; TNS: n=125) 72.2 (2.1) 67.2 (2.1) 0.041
Global satisfaction (AZLI: n=130; TNS: n=126) 68.9 (2.1) 61.8 (2.2) 0.004
TSQM scales, b Week 20 (after course 3), adjusted mean (SE)
Effectiveness (AZLI: n=118; TNS: n=110) 73.4 (2.3) 57.9 (2.5) b0.001
Side-effects (AZLI: n=118; TNS: n=107) 94.3 (1.6) 92.5 (1.7) 0.328
Convenience (AZLI: n=118; TNS: n=107) 68.0 (2.2) 66.1 (2.4) 0.460
Global satisfaction (AZLI: n=118; TNS: n=109) 75.8 (4.6) 61.7 (4.9) 0.010
a Kaplan–Meier method; p-value based on log rank test.
b Analyzed with ANCOVA models, with terms for treatment, baseline FEV1% predicted, and previous TNS use. CFQ-R respiratory symptoms, PA density, and
weight models included the corresponding values at baseline (Week 0).
c p-Value is for comparison of the number of events for each patient adjusted for time on study through Week 24 based on a negative binomial regression model.
d p-Value based on Fisher's exact test.
e p-Value based on Wilcoxon rank sum test.
CFQ-R = cystic fibrosis questionnaire—revised; CFU = colony forming units; CI = confidence interval; FEV1 = forced expiratory volume in 1 s; IV = intravenous;
NE = not estimable (median time exceeded study duration); PA = Pseudomonas aeruginosa; TSQM = treatment satisfaction questionnaire for medicine.
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of each treatment cycle, and the magnitude of the treatment
differences (AZLI–TNS) were better maintained over the 3
treatment courses.
3.4. Efficacy — extension period
Extension period patients (n=133; AZLI/AZLI: 68; TNS/
AZLI: 65), demonstrated improvements in FEV1% predicted
during each AZLI treatment cycle (Fig. 2D). For AZLI/AZLI-
treated patients, active-comparator period treatment responses
were sustained across the extension period. TNS-treated patients
hadminimal improvements in FEV1% predicted during the active-
comparator period, but after switching to AZLI in the extension
period, their lung function improvements were comparable to the
AZLI/AZLI group.
Increases in body weight were observed for AZLI treated
patients (Online Fig. 3). AZLI/AZLI-treated patients gained
weight across the active-comparator period (mean relative
change from study baseline: 0.55%, 0.86%, and 0.94%, aftercourses 1, 2 and 3) and the 3 extension-period courses (1.30%,
1.76%, and 1.93%, respectively). TNS/AZLI-treated patients
lost weight during the 3 TNS treatment courses (mean relative
change from study baseline: −0.83%, −0.82%, and −0.20%,
respectively) and had increases in weight after switching to
AZLI for the 3 extension-period courses (0.64%, 1.43%, and
1.43%, respectively).3.5. Safety
Adverse event incidences in the active-comparator period were
comparable between treatment groups, with cough and productive
cough most commonly reported (Table 3). Severe adverse events
were experienced by 22 AZLI-treated (16.2%) and 11 TNS-treated
(8.3%) patients (p=0.063; Fisher's exact test), most commonly
cough (AZLI: n=7/22; TNS: n=4/11) and productive cough
(AZLI: n=4/22; TNS: n=5/11). Adverse events considered by
investigators as treatment‐related were reported for 22.8% of
AZLI-treated (n=31/136) and 12.9% of TNS‐treated (n=17/132)
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Fig. 3. Kaplan–Meier estimates for the time to need for IV antipseudomonal
antibiotics for a respiratory event. An independent, blinded committee reviewed IV
antipseudomonal antibiotic use in the active-comparator period and identified those
that were respiratory events. Patients without events were considered as right‐
censored; time to censoringwas the number of days from baseline (Day 0) to the date
of completion of the active-comparator period or early withdrawal. Time to need was
the number of days from baseline (Day 0) to the date of need. The log‐rank test was
used to compare AZLI and TNS among all ITT patients.
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n=19/31; TNS: n=14/17).
Fifteen patients discontinued treatment due to adverse events
(AZLI: 9; TNS: 1) or unspecified safety and/or tolerability reasons
(TNS: 5), most commonly productive cough (AZLI: 3) and
hemoptysis (AZLI: 3). Fourteen of these 15 patients subsequently
discontinued the study for safety or tolerability reasons (AZLI: 3;
TNS: 5), consent withdrawn (AZLI: 3, TNS: 1), or investigator
decision (AZLI: 2; Fig. 1).
As was observed for the active-comparator period, cough
(n=92/133; 69.2%) and productive cough (n=62/133; 46.2%)Table 3
Adverse events occurring during the active-comparator period for ≥10% patients in
Incide
Adverse event a AZLI
Cough 96 (7
Productive cough 70 (5
Pyrexia 43 (3
Oropharyngeal pain 36 (2
Dyspnea 32 (2
Hemoptysis 31 (2
Rales 30 (2
Headache 29 (2
Nasal congestion 29 (2
Rhinorrhea 25 (1
Exercise tolerance decreased 25 (1
Fatigue 24 (1
Decreased appetite 19 (1
Abdominal pain 18 (1
Respiratory tract congestion 16 (1
Wheezing 16 (1
Chest discomfort 14 (1
Nausea 14 (1
Vomiting 14 (1
Pulmonary function test decreased 11 (8
Breath sounds abnormal 8 (5
a Adverse events are coded with Medical Dictionary for Regulatory Activities (Mwere the most commonly reported adverse events in the extension
period. Severe adverse events were experienced by 15/133 (11.3%)
patients, most commonly cough (n=7/133), productive cough
(n=5/133), and pyrexia (n=5/133). One life-threatening event
was reported (lung infiltration unrelated to treatment). Two
patients died due to complications of CF disease; both deaths
were considered unrelated to treatment.
Adverse events considered by investigators as treatment‐related
were reported for 6.8% of patients (n=9/133), most commonly
respiratory incidents (n=6/133).
3.6. Microbiology
In the active-comparator period, no changes (≥4-fold) were
observed in MIC50 values of any antibiotics for all PA isolates in
both treatment groups and the proportion of AZLI-treated patients
with PA isolates with an aztreonam MICN8 μg/mL (parenteral
breakpoint [19]) increased from 33.9% to 49.1%. The percentage
of patients with multi‐drug resistantPAwas comparable at baseline
and Week 24. No clinically concerning changes were observed in
PA susceptibility to other aminoglycoside, quinolone, or beta‐
lactam antibiotics. The prevalence of other respiratory pathogens
remained similar for both treatment groups.
During the extension period, AZLI/AZLI patients had no
changes (≥4-fold) observed in MIC50 values of any antibiotics
for all PA isolates, except for 3 intermittent increases in aztreonam
and 1 intermittent increase in ticarcillin/clavulanate. TNS/
AZLI-treated patients had no changes (≥4‐fold) during either
period in MIC50 values of any antibiotics for all PA isolates.
The proportion of AZLI/AZLI-treated patients with PA
isolates with an aztreonam MICN8 μg/mL increased from
35.2% to 50.0% during the study. The proportion of TNS/
AZLI‐treated patients with PA isolates with a tobramycineither treatment group.
nce of adverse event, n (%)
-treated n=136 TNS-treated n=132
0.6) 104 (78.8)
1.5) 79 (59.8)
1.6) 40 (30.3)
6.5) 37 (28.0)
3.5) 36 (27.3)
2.8) 21 (15.9)
2.1) 35 (26.5)
1.3 ) 27 (20.5)
1.3) 26 (19.7)
8.4 ) 33 (25.0)
8.4) 27 (20.5)
7.6) 25 (18.9)
4.0) 19 (14.4)
3.2) 8 (6.1)
1.8) 19 (14.4)
1.8) 20 (15.2)
0.3) 13 (9.8)
0.3) 10 (7.6)
0.3) 14 (10.6)
.1) 17 (12.9)
.9) 15 (11.4)
edDRA) Version 11.1. Multiple occurrences per patient were counted once.
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active-comparator phase, while the proportion with PA
isolates with an aztreonam MICN8 μg/mL increased from
38.3% to 49.0% during the extension phase. The percentage
of patients with multi‐drug resistant PA was comparable at
study baseline and study end. The prevalence of other
respiratory pathogens remained similar for both treatment
groups. Burkholderia cepacia complex was not isolated
during the study.4. Discussion
Comparative efficacy trials can demonstrate the value of newly
developed therapies compared with existing therapies. For CF
patients, inhaled antibiotics comparisons can be assessed by lung
function, measurements of pulmonary exacerbations, respiratory
symptoms, surrogate markers of health (e.g., weight gain/loss),
adverse events, and changes in microbial antibiotic sensitivity.
Crossover designs, such as the open-label extension in this study,
can also show incremental benefits of a new therapy.
This study demonstrated superiority of AZLI to TNS in lung
function improvement after 28 days and superiority across 3
treatment courses. Compared with TNS, AZLI also reduced the
total number of pulmonary exacerbations, delayed time to need
for additional antibiotic therapies, improved respiratory symp-
toms, and increased weight in a contemporary CF population
that was considered stable at baseline. Importantly, patients
with prior TNS experience responded to AZLI treatment during
the active-comparator portion of the study, and patients treated
with TNS in the active-comparator portion of the study showed
incremental improvement in the cross-over period, achieving
the same benefit in lung function responses as patients initially
randomized to AZLI.
Sputum PA density decreased equally for TNS and AZLI
groups in the current study, suggesting a similar antibacterial
effect for the 2 treatment groups. Given confounding factors
(e.g., patient ability to produce sputum throughout a clinical
trial; regional intra-pulmonary variability of bacterial density)
these data must be interpreted with caution, in light of
the marked differences in clinical benefit favoring AZLI
treatment.
AZLI was well tolerated with an adverse-event profile
consistent with previous clinical trials. Drug‐related adverse
events were reported for significantly more AZLI‐treated than
TNS-treated patients. In this unblinded study, investigators
may have attributed more adverse events to a less familiar
antibiotic (AZLI) than to a drug used for over a decade (TNS).
Also, patients with a history of intolerance to TNS were excluded
from study enrollment. Concerning changes in PA susceptibilities
were not observed for either treatment group.
The AZLI–TNS treatment effect for FEV1% predicted at Day
28 in this study (+7.80%)was comparable to the treatment effects
observed in previous phase 3 AZLI‐placebo studies (+10.2%;
+6.6%) [11,12]. The 0.55% improvement in FEV1% predicted
observed at Day 28 of TNS treatment in this study was much
smaller than the 9.7% TNS‐placebo treatment effect observed atDay 28 in early TNS studies, but is comparable to the effect seen
in a more recent study with TNS-experienced patients [9,11].
On average, decreases in FEV1 of 1 to 4% predicted per year
are observed for CF patients [20–22]. Pulmonary exacerbations
are associatedwith step-wise loss of lung function and deleterious
effects on quality of life. These events also incur significant costs,
whether treated in-hospital or with home IV-antibiotics [23].
AZLI‐treated patients experienced a prolonged time-to-need for
IV antipseudomonal antibiotics for a respiratory event compared
with TNS-treated patients, and had significantly fewer respiratory
hospitalizations and respiratory events requiring IV and/or
additional inhaled antipseudomonal antibiotics. Patients receiving
additional antipseudomonal antibiotics for exacerbations were
allowed to continue in the study; these additional treatments likely
supplemented their FEV1 responses over the course of the trial.
While FEV1 responses at the end of each off-treatment cycle were
similar for both treatment groups, significantly more IV/inhaled
antibiotics were used for TNS‐treated patients in order to maintain
lung function; 38% of AZLI‐treated patients vs. 58% of
TNS-treated patients received additional therapies during the
active‐comparator portion of the study. After adjusting for the
use of additional antipseudomonal antibiotics, the AZLI–TNS
treatment differences were better maintained across 3 treatment
cycles. Although FEV1 was below baseline for both groups at
Week 24, the AZLI treatment effects in each of the extension
phase courses were comparable in magnitude to those observed
for the first 3 cycles. Similarly, favorable treatment responses to
repeated AZLI courses were observed during a prior 18‐month
study [13]. Additional evidence of improved patient well-being
associated with AZLI treatment was the increase above baseline
values for body weight observed during AZLI treatment compared
with the decrease during TNS treatment.
The open-label design is a limitation of this study; differences
in taste, administration frequency, and approved nebulizers did
not allow blinding the study. A double‐dummy design would
impose an excessive treatment burden on study participants. In
this open-label study, AZLI‐treated patients with TNS experience
may have been more likely to report improvements in respiratory
symptoms or treatment satisfaction with AZLI than with TNS. A
further limitation is that only 4.9% of the patients enrolled in this
study were 6 to 12 years of age (n=13/268). This reflects the
contemporary CF population; children with CF are generally
not chronically infected with PA and they do not tend to have
diminished lung function. Results from an ongoing clinical
trial assessing the safety of AZLI in children with CF and
chronic PA infection will provide more data for the pediatric
population (Clinicaltrials.gov: NCT01404234).
Another perceived limitation is the inclusion of TNS-
experienced patients. Since TNS is standard of care for CF
patients with chronic PA infection, enrolling only TNS-naïve
patients would not be feasible. Further, in a comparative efficacy
study, it is necessary to enroll the group of patients receiving
existing standard of care therapy, to allow generalization of the
results to the overall patient population. Although treatment
paradigms vary by both country and center, several lines of
evidence suggest that the population in this study was represen-
tative of the general CF population with chronic PA infection.
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registry received inhaled tobramycin [22]. Further, 82% of patients
in a recent international open‐label, prospective, randomized trial
had received inhaled tobramycin prior to screening [24].
In the current study, AZLI (75 mg; 3 times a day) and TNS
(300 mg; 2 times a day) doses were used in accordance with
the respective EMA and FDA approved labels. Dosing
regimens have been established during the development of
each drug on the basis of efficacy results in clinical trials
[3,4,7,8]. The difference in the approved dosing frequencies, in
part, reflects the difference in the mechanisms of action for these
2 antibiotics. The antimicrobial activity of aztreonam is time
dependent, relating to the elapsed time above a specific drug
concentration in the airway. The activity of tobramycin is
concentration dependent, thus its antibiotic effects will depend on
the peak drug concentration achieved in the airway. The
availability of 2 inhaled antibiotics approved for use in CF patients
with chronic PA infection now provides the opportunity to
prospectively study the benefit of a continuous alternating therapy
regimen of 2 antibiotics compared to the standard of care
alternate-month monotherapy. Eliminating off-treatment periods
has the potential to better preserve lung function, control
respiratory symptoms, and reduce the rates of acute pulmonary
exacerbations and hospitalizations.
In conclusion, AZLI demonstrated statistical superiority to
TNS over the first comparative treatment course, and
maintained superiority to TNS across 3 treatment courses in a
patient cohort that was representative of the current CF
population receiving standard of care treatment for chronic
PA infection. AZLI-treated patients had fewer respiratory
hospitalizations than TNS‐treated patients and less frequently
used IV or additional inhaled antipseudomonal antibiotics for
respiratory events. This study demonstrates that AZLI provides an
effective and well tolerated treatment option for CF patients with
chronic airway PA infection.
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